1359TiP RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study

Abstract

Immune checkpoint inhibitors combined with platinum doublet chemotherapy (PDCT) have improved outcomes for NSCLC; however, some patients with metastatic NSCLC may not benefit from this strategy due to intrinsic or acquired resistance. Lymphocyte-activation gene 3 (LAG-3) is a inhibitory immune checkpoint that is a marker of T-cell exhaustion limiting their activity. RELA is a LAG-3-blocking monoclonal antibody that restores effector function in exhausted T cells. The combination of RELA + NIVO demonstrated superior progression-free survival (PFS) benefit in previously untreated melanoma and was well tolerated with no new safety signals.